Sugi Predict

Sugi Predict / Compounds / SCHEMBL205029

SCHEMBL205029

SCHEMBL205029

CNCc1ccc(C(=O)OC)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.63
▸ CA1 P00915 6/20 0.60
▸ CA2 P00918 6/20 0.60
▸ CYP4A11 Q02928 2/20 0.58
▸ HPGD P15428 2/20 0.57
▸ LMNA P02545 1/20 0.57
▸ CYP4F2 P78329 1/20 0.56
▸ CA12 O43570 2/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ CA14 Q9ULX7 2/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ CA7 P43166 1/20 0.55
▸ MAPT P10636 2/20 0.55
▸ TSHR P16473 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9638765 0.98 LOXL2 (0.61) LOXL2CA1CA2CYP4A11HPGD
SCHEMBL23063806 0.94 CA1 (0.59) LOXL2CA1CA2CYP4A11HPGD
SCHEMBL9016956 0.86 LMNA (0.68) LOXL2CA1CA2CYP4A11HPGD
SCHEMBL69454 0.85 LOXL2 (0.70) LOXL2CA1CA2CYP4A11HPGD
4-Methylbenzoic Acid Methyl Ester SCHEMBL28490393 0.85 CA1 (0.63) CA1CA2HPGDTDP1MAPT
SCHEMBL15689805 0.85 LMNA (0.63) LOXL2CA1CA2CYP4A11HPGD
SCHEMBL27986596 0.85 LOXL2 (0.46) LOXL2CA1CA2CYP4A11HPGD
SCHEMBL27916669 0.85 LOXL2 (0.46) LOXL2CA1CA2CYP4A11HPGD
SCHEMBL2227574 0.84 LOXL2 (0.63) LOXL2CA1CA2CYP4A11HPGD
Hydrochloric Acid SCHEMBL15393160 0.84 LMNA (0.66) LOXL2CA1CA2CYP4A11HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics PROSETTA BIOSCIENCES INC (US) 2026-05-14 — — US disclosed
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2025-11-04 — — US disclosed
US-20240398823-A1 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 TAIPEI MEDICAL UNIVERSITY (TW) 2024-12-05 — — US disclosed
EP-4402124-A1 NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS Prosetta Biosciences, Inc. (US) 2024-07-24 — — EP disclosed
EP-4399198-A2 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 Taipei Medical University (TW) 2024-07-17 — — EP disclosed
CN-118302401-A Dual inhibitors of histone deacetylase 6 and heat shock protein 90 台北医学大学 2024-07-05 — — CN disclosed
WO-2024144088-A1 MET PROTEIN DEGRADATION INDUCING COMPOUND ONCOZEN CO., LTD. (KR) 2024-07-04 — — WO disclosed
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2024-06-25 — — US disclosed
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2024-06-25 — — US disclosed
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2024-06-25 — — US disclosed
US-6835731-B2 Viricides; antiinflammatory agents; antiallergens; antiarthritic agents ANORMED, INC. (CA) 2004-12-28 — — US disclosed
WO-2004064721-A2 A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2004-08-05 — — WO disclosed
EP-1317443-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 — — EP disclosed
US-20020147192-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2002-10-10 — — US disclosed
WO-2002022599-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 — — WO disclosed
EP-0290558-B1 ANTIFOLATE AGENTS BTG INTERNATIONAL LIMITED (GB) 1993-06-16 — — EP disclosed
US-5166403-A Liquid crystals SHOWA DENKO K.K. (JP) 1992-11-24 — — US disclosed
US-4992444-A Antitumor agents, skin disorders BRITISH TECHNOLOGY GROUP LIMITED (GB) 1991-02-12 — — US disclosed
EP-0290558-A1 ANTIFOLATE AGENTS. STEVENS MALCOLM FRANCIS GRAHAM (GB) 1988-11-17 — — EP disclosed
WO-1988004293-A1 ANTIFOLATE AGENTS STEVENS MALCOLM FRANCIS GRAHAM (GB) 1988-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics NCOR1, HAVCR2, NR3C1 LOXL2 2438/4885CA1 2888/4885CA2 1795/4885
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 LOXL2 2693/4885CA1 4374/4885CA2 2749/4885
US-20020147192-A1 Chemokine receptor binding heterocyclic compounds CCR2, CXCR3, ACKR3 LOXL2 1914/4885CA1 4024/4885CA2 4304/4885
US-20240398823-A1 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 HSP90AB1, HDAC6, HSP90AB2P LOXL2 2674/4885CA1 2611/4885CA2 2289/4885
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 LOXL2 2693/4885CA1 4374/4885CA2 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.